Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Historical ICPT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Crossed Above 200 DMA | Bullish | -2.58% | |
| Crossed Above 20 DMA | Bullish | -2.58% | |
| Crossed Above 50 DMA | Bullish | -2.58% | |
| Fell Below 200 DMA | Bearish | 2.66% | |
| Fell Below 20 DMA | Bearish | 2.66% | |
| Fell Below 50 DMA | Bearish | 2.66% | |
| Inside Day | Range Contraction | 2.66% | |
| Crossed Above 200 DMA | Bullish | -4.28% | |
| Crossed Above 20 DMA | Bullish | -4.28% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 2 % | about 11 hours ago |
| Down 1% | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 12 hours ago |
| Fell Below 200 DMA | about 12 hours ago |
| Possible NR7 | about 12 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/23/2022
Intercept Pharmaceuticals, Inc. Description
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Diarrhea Hepatology Liver Disease Fibrosis Digestive Diseases Bile Acid Chronic Liver Disease Chronic Liver Diseases Primary Biliary Cholangitis Cirrhosis Farnesoid X Receptor Fxr Obeticholic Acid
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.94 |
| 52 Week Low | 11.6 |
| Average Volume | 799,795 |
| 200-Day Moving Average | 17.35 |
| 50-Day Moving Average | 16.75 |
| 20-Day Moving Average | 16.64 |
| 10-Day Moving Average | 16.44 |
| Average True Range | 1.21 |
| ADX | 18.29 |
| +DI | 23.01 |
| -DI | 12.13 |
| Chandelier Exit (Long, 3 ATRs) | 14.66 |
| Chandelier Exit (Short, 3 ATRs) | 18.07 |
| Upper Bollinger Bands | 18.31 |
| Lower Bollinger Band | 14.97 |
| Percent B (%b) | 0.61 |
| BandWidth | 20.09 |
| MACD Line | 0.12 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.1362 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.84 | ||||
| Resistance 3 (R3) | 19.02 | 18.60 | 18.53 | ||
| Resistance 2 (R2) | 18.60 | 18.13 | 18.50 | 18.43 | |
| Resistance 1 (R1) | 17.80 | 17.84 | 17.59 | 17.61 | 18.33 |
| Pivot Point | 17.37 | 17.37 | 17.27 | 17.28 | 17.37 |
| Support 1 (S1) | 16.57 | 16.90 | 16.36 | 16.39 | 15.67 |
| Support 2 (S2) | 16.15 | 16.61 | 16.05 | 15.57 | |
| Support 3 (S3) | 15.35 | 16.15 | 15.47 | ||
| Support 4 (S4) | 15.16 |
